HRP20021009B1 - Postupak za pripremu pripravka - Google Patents

Postupak za pripremu pripravka

Info

Publication number
HRP20021009B1
HRP20021009B1 HR20021009A HRP20021009A HRP20021009B1 HR P20021009 B1 HRP20021009 B1 HR P20021009B1 HR 20021009 A HR20021009 A HR 20021009A HR P20021009 A HRP20021009 A HR P20021009A HR P20021009 B1 HRP20021009 B1 HR P20021009B1
Authority
HR
Croatia
Prior art keywords
preparation
solution
homogeneous dispersion
procedure
compound
Prior art date
Application number
HR20021009A
Other languages
English (en)
Croatian (hr)
Inventor
Busson Patrick
Schroeder Marco
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20021009(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20021009A2 publication Critical patent/HRP20021009A2/hr
Publication of HRP20021009B1 publication Critical patent/HRP20021009B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20021009A 2000-06-27 2001-06-18 Postupak za pripremu pripravka HRP20021009B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113535 2000-06-27
PCT/EP2001/006834 WO2002000201A2 (en) 2000-06-27 2001-06-18 Method for preparing a composition

Publications (2)

Publication Number Publication Date
HRP20021009A2 HRP20021009A2 (en) 2004-02-29
HRP20021009B1 true HRP20021009B1 (hr) 2011-07-31

Family

ID=8169074

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20021009A HRP20021009B1 (hr) 2000-06-27 2001-06-18 Postupak za pripremu pripravka

Country Status (37)

Country Link
US (3) US6534087B2 (https=)
EP (1) EP1296656B1 (https=)
JP (2) JP4149803B2 (https=)
KR (1) KR100557845B1 (https=)
CN (1) CN1236764C (https=)
AR (1) AR029278A1 (https=)
AT (1) ATE334662T1 (https=)
AU (2) AU8184601A (https=)
BR (1) BRPI0112014B1 (https=)
CA (1) CA2411153C (https=)
CY (1) CY1105714T1 (https=)
CZ (1) CZ301813B6 (https=)
DE (1) DE60121953T2 (https=)
DK (1) DK1296656T3 (https=)
EC (1) ECSP024401A (https=)
EG (1) EG24141A (https=)
ES (1) ES2269441T3 (https=)
HR (1) HRP20021009B1 (https=)
HU (1) HU229550B1 (https=)
IL (2) IL153282A0 (https=)
JO (1) JO2247B1 (https=)
MA (1) MA26922A1 (https=)
ME (1) ME00672B (https=)
MX (1) MXPA02012583A (https=)
MY (1) MY129798A (https=)
NO (1) NO332181B1 (https=)
NZ (1) NZ523024A (https=)
PE (1) PE20020101A1 (https=)
PL (1) PL203804B1 (https=)
PT (1) PT1296656E (https=)
RU (1) RU2244542C2 (https=)
SI (1) SI1296656T1 (https=)
TW (1) TWI278325B (https=)
UY (1) UY26799A1 (https=)
WO (1) WO2002000201A2 (https=)
YU (1) YU96602A (https=)
ZA (1) ZA200209649B (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
PL203804B1 (pl) * 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
KR100625399B1 (ko) * 2002-04-26 2006-09-20 에프. 호프만-라 로슈 아게 리파아제 억제제 및 글루코마난을 포함하는 약학 조성물
KR100517072B1 (ko) * 2002-11-25 2005-09-26 주식회사 태평양 폴리올/고분자 마이크로캡슐 및 이를 이용한 효소 안정화방법
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
CA2548892C (en) * 2003-12-12 2015-10-27 Eran Eilat Compositions for treatment of ear disorders and methods of use thereof
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
EP1737405A2 (en) * 2004-04-06 2007-01-03 RPG Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
JP4329816B2 (ja) * 2004-09-15 2009-09-09 萬有製薬株式会社 サンプリング方法、サンプリング装置、ｌｏｇＤ測定方法及びｌｏｇＤ測定システム
EP2163196A3 (en) * 2004-12-31 2010-11-03 Mikhail Yurievich Gotovsky Device for measuring the presence of foreign substances in a living organism and for individually selecting preparations for increasing an organism's life activity
US20060198856A1 (en) * 2005-03-01 2006-09-07 Keith Whitehead Ibuprofen suspension stabilized with docusate sodium
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US7984717B2 (en) * 2005-04-29 2011-07-26 Medtronic, Inc. Devices for augmentation of lumen walls
US20070060610A1 (en) * 2005-06-16 2007-03-15 Wempe Michael F Methods and pharmaceutical formulations for increasing bioavailability
WO2006136196A1 (en) * 2005-06-21 2006-12-28 V. Mane Fils Gellan seamless breakable capsule and process for manufacturing thereof
WO2006136197A1 (en) 2005-06-21 2006-12-28 V. Mane Fils Smoking device incorporating a breakable capsule, breakable capsule and process for manufacturing said capsule
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007079147A2 (en) 2005-12-28 2007-07-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
FR2895908B1 (fr) * 2006-01-12 2008-03-28 France Etat Procede de fabrication d'une forme pharmaceutique de phosphate d'oseltamivir
EP1987825B1 (en) 2006-02-20 2018-09-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising oseltamivir phosphate
JP2009530614A (ja) 2006-03-16 2009-08-27 デューク ユニバーシティ フーリエ領域光コヒーレンス・トモグラフィーに基づく実時間直角位相投影を実行するための方法、システム及びコンピュータプログラム製品
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
KR100812824B1 (ko) 2006-09-27 2008-03-12 주식회사 제닉 키토산과 폴리에틸렌글리콜을 이용한 생체친화성 저독성필름
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
AU2008254748A1 (en) * 2007-05-18 2008-11-27 Tti Ellebeau, Inc. Transdermal delivery devices assuring an improved release of an active principle through a biological interface
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
WO2010111565A2 (en) 2009-03-27 2010-09-30 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2435554B1 (en) 2009-05-26 2017-07-26 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
AU2010301135A1 (en) * 2009-09-29 2012-04-12 Michael Burnet Novel pesticide formulations
KR100940745B1 (ko) * 2009-10-15 2010-02-04 광동제약 주식회사 오를리스타트 및 아타풀지트 함유 복합제의 코팅펠렛 및 이를 이용한 제제
PL2529004T3 (pl) 2010-01-28 2017-12-29 Advanced Bionutrition Corporation Sucha szklista kompozycja zawierająca bioaktywny materiał
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101021030B1 (ko) * 2010-03-25 2011-03-09 엘지이노텍 주식회사 형광체 코팅방법, 발광장치 제조방법 및 코팅된 형광체
DK2557151T3 (en) * 2010-04-07 2017-12-11 Mitsubishi Gas Chemical Co S-adenosyl-L-methionine-containing dry yeast composition with excellent storage stability and process for preparing the same
AR082682A1 (es) 2010-08-13 2012-12-26 Advanced Bionutrition Corp Composicion estabilizadora de almacenamiento en seco para materiales biologicos
AU2011320159B2 (en) 2010-10-29 2016-12-22 Western University Of Health Sciences Ternary mixture formulations
EP2680815B1 (en) 2011-03-01 2016-08-17 The Procter and Gamble Company Porous disintegratable solid substrate for personal health care applications
MX356072B (es) 2012-03-23 2018-05-14 Advanced Bionutrition Corp Composicion estabilizante para materiales biologicos.
CN103222964B (zh) * 2013-01-29 2014-10-08 青岛大学 一种奥利司他口服制剂及其制备方法
GB2524496A (en) * 2014-03-24 2015-09-30 British Airways Plc Dynamic tracking and control of passenger travel progress
PY1639434A (es) 2015-06-25 2018-08-01 Ascus Biosciences Inc Procedimientos, aparatos y sistemas para el analisis de cepas de microorganismos provinientes de comunidades complejas y heterogenas. prediccion e identificacion de relaciones..//.
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
CA3048246A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
AU2017388535A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
WO1998002240A1 (en) * 1996-07-15 1998-01-22 Universal Preservation Technologies, Inc. Preservation by foam formation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
US4489438A (en) * 1982-02-01 1984-12-18 National Data Corporation Audio response system
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
ATE216577T1 (de) 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
US5560921A (en) 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US5343672A (en) 1992-12-01 1994-09-06 Scherer Ltd R P Method for manufacturing freeze dried dosages in a multilaminate blister pack
WO1994018951A1 (en) * 1993-02-23 1994-09-01 Warner-Lambert Company A process for the preparation of substantially alcohol free pharmaceutical compositions
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5536264A (en) * 1993-10-22 1996-07-16 The Procter & Gamble Company Absorbent composites comprising a porous macrostructure of absorbent gelling particles and a substrate
CN100409844C (zh) 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
CN103772231B (zh) 1995-02-27 2016-02-03 吉里德科学公司 新颖化合物，其合成方法及治疗用途
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
ES2217410T3 (es) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. Forma de dosificacion oral de rapida desintegracion.
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
JPH11137208A (ja) 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
AU3705799A (en) * 1998-04-09 1999-11-01 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
WO2000009123A1 (en) * 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
GB9827423D0 (en) * 1998-12-11 1999-02-03 Relax Limited Method of drying a solution
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
GB9904629D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
FR2791569B1 (fr) * 1999-03-31 2003-05-09 Pf Medicament Composition ou structure microporeuse expansee isotrope a dissolution rapide a usage pharmaceutique, veterinaire, dietetique, alimentaire ou cosmetique et son procede d'obtention
PL203804B1 (pl) * 2000-06-27 2009-11-30 Hoffmann La Roche Sposób wytwarzania kompozycji farmaceutycznej w postaci spoistej, płytkowej, piankowej, gąbczastej lub ciastowatej struktury i kompozycja farmaceutyczna otrzymana tym sposobem

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523106A (en) * 1994-02-03 1996-06-04 Nabisco, Inc. Juice-based expanded snacks and process for preparing them
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
WO1998002240A1 (en) * 1996-07-15 1998-01-22 Universal Preservation Technologies, Inc. Preservation by foam formation

Also Published As

Publication number Publication date
YU96602A (sh) 2005-03-15
ZA200209649B (en) 2004-03-10
EG24141A (en) 2008-08-06
MEP90608A (bs) 2011-12-20
UY26799A1 (es) 2001-12-28
HRP20021009A2 (en) 2004-02-29
KR20030023880A (ko) 2003-03-20
MXPA02012583A (es) 2003-04-10
HK1058314A1 (en) 2004-05-14
BRPI0112014B1 (pt) 2016-09-13
JP4149803B2 (ja) 2008-09-17
AU2001281846B2 (en) 2006-04-27
NO332181B1 (no) 2012-07-16
CA2411153C (en) 2007-01-30
CN1438880A (zh) 2003-08-27
PE20020101A1 (es) 2002-02-12
WO2002000201A3 (en) 2002-04-18
BR0112014A (pt) 2003-05-13
ME00672B (me) 2011-12-20
IL153282A (en) 2008-03-20
CY1105714T1 (el) 2010-12-22
JO2247B1 (en) 2004-10-07
TWI278325B (en) 2007-04-11
SI1296656T1 (sl) 2006-12-31
RU2244542C2 (ru) 2005-01-20
JP2007302683A (ja) 2007-11-22
CN1236764C (zh) 2006-01-18
ECSP024401A (es) 2003-02-06
NO20026197D0 (no) 2002-12-23
US7074431B2 (en) 2006-07-11
WO2002000201A2 (en) 2002-01-03
PL203804B1 (pl) 2009-11-30
NO20026197L (no) 2002-12-23
US20020018812A1 (en) 2002-02-14
US6534087B2 (en) 2003-03-18
IL153282A0 (en) 2003-07-06
PL365803A1 (en) 2005-01-10
US20030039614A1 (en) 2003-02-27
PT1296656E (pt) 2006-12-29
HUP0302060A3 (en) 2006-07-28
CZ301813B6 (cs) 2010-06-30
HU229550B1 (en) 2014-01-28
ES2269441T3 (es) 2007-04-01
CZ2003212A3 (cs) 2003-06-18
KR100557845B1 (ko) 2006-03-10
MA26922A1 (fr) 2004-12-20
US20060134205A1 (en) 2006-06-22
MY129798A (en) 2007-04-30
ATE334662T1 (de) 2006-08-15
AU8184601A (en) 2002-01-08
AR029278A1 (es) 2003-06-18
DK1296656T3 (da) 2006-11-27
DE60121953T2 (de) 2007-03-08
EP1296656B1 (en) 2006-08-02
NZ523024A (en) 2004-08-27
HUP0302060A2 (hu) 2003-09-29
EP1296656A2 (en) 2003-04-02
DE60121953D1 (de) 2006-09-14
JP2004501184A (ja) 2004-01-15
CA2411153A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
HRP20021009B1 (hr) Postupak za pripremu pripravka
EP1136068A3 (en) Powder containing physiologically active peptide
DE69811233D1 (de) Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
WO2002026733A3 (en) sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES
DE69820973D1 (de) Biphasige arzneimiteldosierungsform aus vielen komponenten, die stoffe enthält, die die verteilung der arzneimittel beeinflussen können
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
WO2002048147A3 (en) Pyrazolopyridines
WO2002096432A3 (en) Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
DK0973506T3 (da) Fremgangsmåde til fremstilling af faste farmaceutiske doseringsformer
DE60112330D1 (en) Pyrazolopyridinderivate
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
DK1534352T3 (da) Implantat til transport og afgivelse af farmakologisk aktive midler såvel som en fremgangsmåde til fremstilling af samme
ATE369840T1 (de) Orale zusammensetzungen von itraconazol und verfahren zu herstellung derselbigen
AU2002248531A1 (en) Pyrazolopyriadine derivatives
WO2002004412A3 (en) Tyrosine derivatives as phosphatase inhibitors
WO2003035651A3 (fr) Derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
WO2002003973A3 (en) Compositions comprising isosorbide dinitrate and methods for treatment of anal fissure
ITMI951621A1 (it) Composizione farmaceutica per abbassare la pressione del sangue e procedimento per la sua preparazione
DK1335922T3 (da) Fremgangsmåde til fremstilling af 4'-demethyl-4'-O-substituerede 1-deoxypodophyllotoxinderivater og geometriske isomerer deraf og anticancersammensætninger, der indeholder samme
WO2003035043A3 (en) Pharmaceutical formulation comprising more than 15% tamoxifen

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: CHEPLAPHARM ARZNEIMITTEL GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190606

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200608

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20210618